Lifeboat Foundation

Biodiversity conservation, public health and improved livelihoods — dr gladys kalema-zikusoka, founder and CEO, conservation through public health.

Dr. Gladys Kalema-Zikusoka, is the Founder and CEO of Conservation Through Public Health (CTPH — https://ctph.org/), a 16-year old non-profit organization, based in Uganda, that promotes conservation by improving the quality of life of people and wildlife to enable them to coexist in and around protected areas in Africa, and she has become one of the leading conservationists and scientists working to save the critically endangered mountain gorillas of East Africa.

Continue reading “Dr. Gladys Kalema-Zikusoka, Founder and CEO, Conservation Through Public Health (CTPH), Uganda” »

Bridging Technology And Medicine For The Modern Healthcare Ecosystem — Dr. Mona G. Flores, MD, Global Head of Medical AI, NVIDIA.

Dr. Mona Flores M.D., is the Global Head of Medical AI, at NVIDIA (https://blogs.nvidia.com/blog/author/monaflores/), the American multinational technology company, where she oversees the company’s AI initiatives in medicine and healthcare to bridge the chasm between technology and medicine.

Continue reading “Dr. Mona Flores, M.D., Global Head of Medical AI, NVIDIA — Bridging Technology And Medicine” »

U.S. health officials on Wednesday reported the country’s first case of the Omicron variant of the coronavirus, in a person in California.

The Covid-19 case was identified by the California and San Francisco health departments in a person who had traveled to South Africa and returned on Nov. 22, the Centers for Disease Control and Prevention said in a release. The individual, who was fully vaccinated with the Moderna shot but had not received a booster, had mild symptoms and has since recovered, federal and local officials said. The person has been isolating since testing positive on Nov. 29. All close contacts have tested negative thus far.

The discovery of Omicron in the United States is not a surprise. Upon characterizing the mutations in the variant, scientists in South Africa last week quickly raised the world’s alarms about the potential threat it posed, but it had already started to circulate silently. Some two dozen countries, from the United Kingdom to Australia to Israel, have already reported cases, many in travelers.

The new Covid variant omicron will likely “overwhelm the whole world” in the coming months, according to Singapore doctor Leong Hoe Nam.

Here’s a quick reminder that one of the expected results of the current pandemic is the slow, controlled, but inevitable destruction of the Canadian economy as government assets are secretly pulled out of circulation and redistributed to international bankers and their wealthiest clients.

Prime Minister Justin Trudeau’s Liberal government is asking Parliament to approve billions in new spending during a brief four-week sitting in Ottawa, but is facing questions because it has not released a full accounting of how it spent more than $600Bln last year.

Harrison.ai, a Sydney-based company that creates medical devices with AI technology, announced today it has raised $129 million AUD (about $92.3 million USD) in what it called one of the largest Series B rounds ever for an Australian startup.

The funding was led by returning investor Horizons Ventures and included participation from new investors Sonic Healthcare and I-MED Radiology Network. Existing backers Blackbird Ventures and Skip Capital also returned for the round, which brings Harrison.ai’s total raised over the past two years to $158 million AUD.

Harrison.ai announced it has also formed a joint venture with Sonic Healthcare, one of the world’s largest medical diagnostics providers, to develop and commercialize new clinical AI solutions in pathology. The partnership will focus first on histopathology, or the diagnosis of tissue diseases.

Scientists say they have made a major step forward in storing information in molecules of DNA.

The market introduction of the MR-Linac technology improves the patient care via the real-time imaging of the targeted PTVs. Conventional Water Phantoms with ferromagnetic material become prohibited due to safety reasons. To overcome this situation, LAP introduced the MR-compatible Water Phantom THALES 3D MR SCANNER. Dr Thierry Gevaert, medical physicist and co-ordinator at the UZ Brussel institute, will share his experience with the THALES 3D MR SCANNER during the commissioning of the MRIdian Linac of Viewray. Furthermore, he will highlight which benefits played an important role for his clinical workflow.

During the webinar you will also learn more about the THALES technology for commissioning and quality-assurance processes of conventional Linacs.

ISM001-055 demonstrated highly promising results in multiple preclinical studies including in vitro biological studies, pharmacokinetic and safety studies. The compound significantly improved myofibroblast activation which contributes to the development of fibrosis. ISM001-055’s novel target is potentially relevant to a broad range of fibrotic indications.

“We are very pleased to see Insilico Medicine’s first antifibrotic drug candidate entering into the clinic,” said Feng Ren 0, PhD, CSO of Insilico Medicine. “We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge the drug candidate is the first ever AI-discovered novel molecule based on an AI-discovered novel target. We have leveraged our end-to-end AI-powered drug discovery platform, including the usage of generative biology and generative chemistry, to discover novel biological targets and generate novel molecules with drug-like properties. ISM001-055 is the first such compound to enter the clinic, and we expect more to come in the near future [1].”

Previously, Insilico Medicine demonstrated its ability to generate drug-like hit molecules using AI with the publication of the Generative Tensorial Reinforcement Learning (GENTRL) system for a well-known target in record time [2]. It also demonstrated the target’s proof of concept by applying deep learning techniques for the identification of novel biological targets. This novel antifibrotic program combined these target discovery and generative chemistry capabilities. Notably, Insilico Medicine completed the entire discovery process from target discovery to preclinical candidate nomination within 18 months on a budget of $2.6 million.